论文部分内容阅读
目的为观察膦甲酸钠抗乙型肝炎病毒(HBV)的近期疗效。方法将62例慢性乙型肝炎患者随机分为2组:治疗组30例,在常规保肝治疗的基础上加用膦甲酸钠;对照组32例,仅用常规保肝药物治疗。治疗前后观察患者肝功能、血清HBV DNA含量、乙肝病毒免疫学标志等的变化。结果治疗组中30例治疗前具有消化道症状,治疗后25例有缓解,症状改善率83.33%。其中6例慢重肝患者治疗后存活4例,死亡2例,治愈率为66.67%;对照组25例有症状者中20例有缓解,症状改善率80.00%。两组经统计学处理差异无显著性意义(P>0.05)。结论提示膦甲酸钠具有明显和快速的抑制乙肝病毒复制、降低病毒量的作用,可作为抗病毒序贯疗法的首程用药或联合用药的选择之一。
Objective To observe the short-term efficacy of foscarnet against hepatitis B virus (HBV). Methods Sixty-two patients with chronic hepatitis B were randomly divided into two groups: the treatment group (n = 30) and the control group (n = 32) were treated with conventional hepatoprotective drugs only. Before and after treatment, the changes of liver function, serum HBV DNA level and immunological markers of hepatitis B were observed. Results In the treatment group, 30 patients had gastrointestinal symptoms before treatment. After treatment, 25 patients were relieved, and the symptom improvement rate was 83.33%. Among them, 6 cases of chronic severe hepatitis survived in 4 cases and died in 2 cases, the cure rate was 66.67%. In the control group, 25 cases of symptomatic were relieved and the symptom improvement rate was 80.00%. There was no significant difference between the two groups by statistical analysis (P> 0.05). Conclusions suggest that foscarnet has obvious and rapid inhibition of hepatitis B virus replication and reduce the amount of virus, as an anti-virus sequential therapy of the first course of the drug or combination of options.